Clinical trial · Interventional
A Efficacy and Safety Study of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization
A Phase 2 Trial to Evaluate the Efficacy and the Safety of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization
NCT03745846CI-TRIAL-00035860unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the efficacy and safety of composite gel containing black raspberry extract in removing HPV From patients With cervical intraepithelial neoplasia(CIN) after cervical conization
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Intraepithelial Neoplasia | Cervical Intraepithelial Neoplasia | ONTOLOGY_EXACT | 0.98 |
| HPV | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Composite Gel Containing Black Raspberry | Biological | — | UNRESOLVED |
| placebo | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Composite Gel Containing Black Raspberry
- description
- Drug:Composite Gel Containing Black Raspberry 3,000mg Dosage and duration: 1 preparation every other day for 3 months.
- interventionNames
- Biological: Composite Gel Containing Black Raspberry
- type
- PLACEBO_COMPARATOR
- label
- Composite Gel Containing Black Raspberry-placebo
- description
- Drug:Composite Gel Containing Black Raspberry-placebo 3,000mg Dosage and duration: 1 preparation every other day for 3 months.
- interventionNames
- Biological: placebo
Primary outcomes (1)
- measure
- negative rate
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects were able and willing to sign informed consent. * Patients with CIN who underwent cervical conization were at high risk of persistent HPV infection. * Age must be between 20-55 years old. * Subjects should begin receiving protocol studies at least two months after cervical conization. * Patients must be readily available for study and follow-up. * Patients should not participate in other clinical trials at the same time and agree not to participate in other interventional clinical trials during the protocol study. Except for questionnaires or observational studies. * Patients should have appropriate nutritional status: body mass index BMI ≥ 18 kg / m2, body weight \> 40 kg, serum albumin ≥ 3 g / dL. Exclusion Criteria: Anyone who meets any of the following criteria is not allowed to participate in this test: * Pregnant women, pregnant and lactating women. * Patients who participated in other clinical trials in the past 3 months. * It has a serious primary disease such as cardiovascular and cerebrovascular, hematopoietic system and liver and kidney, or patients with mental illness. * Allergic patients. * People with epidemics such as AIDS. * Suffering from uncontrolled complications, including but not limited to: persistent or active infection; clinically significant healing or non-healing wounds; symptomatic congestive heart failure; unstable angina; clinically significant arrhythmia; A disease that affects research compliance, such as an infectious disease or a mental illness/social condition. * Active, uncontrolled bacterial, viral or fungal infections and require systemic treatment. * The patient has a history of other malignancies or is suffering from malignant tumors and autoimmune diseases. * Have any active disease that may increase the risk of a program study or impair a patient's ability to receive protocol research. * Patients who plan to stay on vacation for 14 days or more during the study period.
References
Publications (0)
Data not yet available
No reference posted for this study.